BioCina Pty Ltd, a global biologics contract development and manufacturing organisation, has formed a strategic alliance with GenomeFrontier Therapeutics AU Pty Ltd, an Australian subsidiary of Taiwan-based GenomeFrontier Therapeutics Inc.
Next generation CAR-T cell products
The collaboration aims to develop next-generation, virus-free chimeric antigen receptor T-cell (CAR-T) products for cancer treatment.
The agreement entails BioCina offering process development and Good Manufacturing Practice (GMP) manufacturing support for Minicircle DNA and Plasmid DNA.
GenomeFrontier will use its proprietary virus-free cell and gene engineering platforms, as well as its Quantum Engine™ cell-engineering system, to produce CAR-T cell therapies intended for a Phase 1 clinical trial. This endeavour comes as a significant step in the ongoing quest for more advanced and accessible cancer therapies.
BioCina CEO Mark W Womack said of the partnership: "We are thrilled to be GenomeFrontier's CDMO partner for this important cancer treatment program, utilising both Minicircle and Plasmid DNA, providing us yet another opportunity to showcase our scientific and technical expertise in support of the CAR-T cell therapy product."
A cancer-free world
GenomeFrontier founder and CEO/CSO Sareina Wu also weighed in: "We believe that a cancer-free world is not only possible but is more real than ever before, due to major advancements in gene therapy.
"Therefore, we passionately strive to provide patients with next-generation virus-free gene therapies that are not only advanced and accessible but also affordable."
About BioCina
BioCina is a leading CDMO that specialises in process development and cGMP clinical and commercial manufacturing across multiple modalities.
Headquartered in Adelaide, South Australia, the company plans to expand its capabilities by adding a 2,000-litre microbial fermenter and large-scale mRNA manufacturing.
About GenomeFrontier
GenomeFrontier focuses on the development of next-generation, virus-free gene therapies. Its proprietary Quantum Engine™ system facilitates the establishment of multiplex gene therapies that are efficacious, safe, and cost-effective.
The company primarily focuses on CAR-T therapies through its Quantum CART™ system.